Ionis Pharmaceuticals (IONS)

$71.19 -1.15 (-1.59%)
Market Cap 11.76B
Revenue (ttm) 943.71M
Net Income (ttm) -381.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40.41%
Debt to Equity Ratio 0.94
Volume 1,972,100
Avg Vol 2,298,408
Day's Range N/A - N/A
Shares Out 165.19M
Stochastic %K 7%
Beta 0.31
Analysts Strong Sell
Price Target $95.39

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 12 at 4:12 AM
$IONS RSI: 29.61, MACD: -1.8243 Vol: 3.51, MA20: 80.22, MA50: 80.86 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_TP888
_TP888 Mar. 5 at 3:58 PM
$IONS | $70.00 | Put | Premium: $368K Ask-heavy - aggressive put buyers.
0 · Reply
StockDreamin
StockDreamin Mar. 5 at 3:47 PM
$IONS come get some $ENSC
0 · Reply
JohnStuartMill
JohnStuartMill Mar. 4 at 1:52 AM
$NMTC Old Saying: "Never look a gift horse in the mouth." Unless of course you are to dense to recognize it. GO biotech's, I own many of them. $ARWR, $IMMX, $IONS, $CMTX
2 · Reply
erevnon
erevnon Mar. 3 at 5:19 PM
Leerink Partners maintains Ionis Pharmaceuticals $IONS at Outperform and raises the price target from $102 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 3 at 4:25 AM
$IONS Share Price: $81.96 Contract Selected: Oct 16, 2026 $82.5 Calls Buy Zone: $9.78 – $12.08 Target Zone: $17.82 – $21.78 Potential Upside: 72% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Feb. 27 at 5:57 PM
Piper Sandler maintains Ionis Pharmaceuticals $IONS at Overweight and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Feb. 27 at 2:42 PM
$IONS Buy Piper Sandler raises target price to $100 from $87
0 · Reply
N_Baker
N_Baker Feb. 27 at 12:37 PM
$IONS biotech leader consolidating watching for next expansion phase
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 2:42 PM
$IONS beats Q4 expectations, but why did shares drop 5%? Despite stronger-than-expected revenue and a narrower loss, Ionis issued a 2026 revenue guidance below the Zacks Consensus Estimate, signaling slower sales uptake for new drugs Tryngolza and Dawnzera. Full analysis here 👉 https://www.zacks.com/stock/news/2875702/ionis-q4-earnings-sales-beat-stock-down-on-soft-2026-outlook?cid=sm-stocktwits-2-2875702-body-35262&ADID=SYND_STOCKTWITS_TWEET_2_2875702_BODY_35262
0 · Reply
Latest News on IONS
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 11, 2026, 4:12 PM EDT - 4 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 9, 2026, 5:57 PM EDT - 5 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript

Ionis announces changes to Board of Directors

Mar 9, 2026, 7:00 AM EDT - 6 days ago

Ionis announces changes to Board of Directors

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Mar 5, 2026, 7:30 AM EST - 10 days ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

BIIB

Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:27 PM EST - 13 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Feb 27, 2026, 7:00 AM EST - 16 days ago

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Ionis Pharmaceuticals: Digesting Recent Events

Feb 27, 2026, 2:54 AM EST - 16 days ago

Ionis Pharmaceuticals: Digesting Recent Events

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Feb 26, 2026, 4:57 PM EST - 16 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Feb 26, 2026, 7:00 AM EST - 17 days ago

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 12:57 PM EST - 18 days ago

Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug

Feb 25, 2026, 12:48 PM EST - 18 days ago

Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Feb 25, 2026, 7:00 AM EST - 18 days ago

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Ionis to present at upcoming investor conferences

Feb 19, 2026, 7:05 AM EST - 24 days ago

Ionis to present at upcoming investor conferences

Ionis updates time for fourth quarter and full year 2025 financial results webcast

Feb 17, 2026, 2:58 PM EST - 26 days ago

Ionis updates time for fourth quarter and full year 2025 financial results webcast

Ionis to hold fourth quarter and full year 2025 financial results webcast

Feb 11, 2026, 7:05 AM EST - 4 weeks ago

Ionis to hold fourth quarter and full year 2025 financial results webcast

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Jan 21, 2026, 7:00 AM EST - 7 weeks ago

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth

Jan 20, 2026, 11:09 AM EST - 7 weeks ago

Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth

Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:16 PM EST - 2 months ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

Jan 12, 2026, 7:00 AM EST - 2 months ago

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Jan 7, 2026, 11:48 AM EST - 2 months ago

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

GSK

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Jan 7, 2026, 2:15 AM EST - 2 months ago

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:05 AM EST - 2 months ago

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Dec 2, 2025, 7:00 AM EST - 3 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

Dec 1, 2025, 7:00 AM EST - 3 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 10:08 AM EST - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 4 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Nov 14, 2025, 7:00 AM EST - 4 months ago

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 13, 2025, 12:41 PM EST - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Nov 13, 2025, 12:39 AM EST - 4 months ago

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Nov 11, 2025, 4:05 PM EST - 4 months ago

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript

Nov 10, 2025, 4:31 PM EST - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript

Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally

Nov 10, 2025, 3:31 PM EST - 4 months ago

Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Nov 10, 2025, 1:37 PM EST - 4 months ago

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Nov 8, 2025, 9:40 AM EST - 4 months ago

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Nov 6, 2025, 8:00 AM EST - 4 months ago

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

Nov 4, 2025, 2:38 PM EST - 4 months ago

Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 6:26 PM EDT - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Oct 23, 2025, 2:10 PM EDT - 5 months ago

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 5 months ago

Ionis to hold third quarter 2025 financial results webcast

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript

Oct 7, 2025, 8:55 PM EDT - 5 months ago

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Oct 7, 2025, 8:33 AM EDT - 5 months ago

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Sep 22, 2025, 9:06 AM EDT - 6 months ago

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 6 months ago

Ionis' brain disorder drug shows promise in clinical trial

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

Sep 22, 2025, 7:00 AM EDT - 6 months ago

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

Sep 19, 2025, 7:00 AM EDT - 6 months ago

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Sep 12, 2025, 7:00 AM EDT - 6 months ago

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 12 at 4:12 AM
$IONS RSI: 29.61, MACD: -1.8243 Vol: 3.51, MA20: 80.22, MA50: 80.86 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_TP888
_TP888 Mar. 5 at 3:58 PM
$IONS | $70.00 | Put | Premium: $368K Ask-heavy - aggressive put buyers.
0 · Reply
StockDreamin
StockDreamin Mar. 5 at 3:47 PM
$IONS come get some $ENSC
0 · Reply
JohnStuartMill
JohnStuartMill Mar. 4 at 1:52 AM
$NMTC Old Saying: "Never look a gift horse in the mouth." Unless of course you are to dense to recognize it. GO biotech's, I own many of them. $ARWR, $IMMX, $IONS, $CMTX
2 · Reply
erevnon
erevnon Mar. 3 at 5:19 PM
Leerink Partners maintains Ionis Pharmaceuticals $IONS at Outperform and raises the price target from $102 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 3 at 4:25 AM
$IONS Share Price: $81.96 Contract Selected: Oct 16, 2026 $82.5 Calls Buy Zone: $9.78 – $12.08 Target Zone: $17.82 – $21.78 Potential Upside: 72% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Feb. 27 at 5:57 PM
Piper Sandler maintains Ionis Pharmaceuticals $IONS at Overweight and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Feb. 27 at 2:42 PM
$IONS Buy Piper Sandler raises target price to $100 from $87
0 · Reply
N_Baker
N_Baker Feb. 27 at 12:37 PM
$IONS biotech leader consolidating watching for next expansion phase
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 2:42 PM
$IONS beats Q4 expectations, but why did shares drop 5%? Despite stronger-than-expected revenue and a narrower loss, Ionis issued a 2026 revenue guidance below the Zacks Consensus Estimate, signaling slower sales uptake for new drugs Tryngolza and Dawnzera. Full analysis here 👉 https://www.zacks.com/stock/news/2875702/ionis-q4-earnings-sales-beat-stock-down-on-soft-2026-outlook?cid=sm-stocktwits-2-2875702-body-35262&ADID=SYND_STOCKTWITS_TWEET_2_2875702_BODY_35262
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 1:29 PM
$IONS beats Q4… and still drops 5%. What’s the market really reacting to? Strong Tryngolza sales pushed Q4 earnings and revenue past estimates, but a soft 2026 revenue outlook and slower uptake for new drugs are clearly hitting sentiment. Is this a short-term overreaction or a warning sign for what’s ahead? Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2875702/ionis-q4-earnings-sales-beat-stock-down-on-soft-2026-outlook?cid=sm-stocktwits-2-2875702-teaser-35226&ADID=SYND_STOCKTWITS_TWEET_2_2875702_TEASER_35226
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 26 at 12:00 PM
$IONS Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
0 · Reply
erevnon
erevnon Feb. 26 at 11:19 AM
Needham maintains Ionis Pharmaceuticals $IONS at Buy and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Feb. 25 at 8:01 PM
Needham⬆️ $IONS' PT to $103 from $90/reit Buy—says Co reported strong Q4 results/has a catalyst rich '26—sees upside to '26 rev as the year progresses—views risk/reward as favorable into the Co's data readouts. $ARWR $GSK RBC Capital reit'd IONIS OP/$95 after IONS reported 4Q25/they caught up w/ the team. Here's what RBC Capital had to say: https://x.com/Quantumup1/status/2026748509702029780?s=20
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 12:08 PM
$IONS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$1.41 down -113.64% YoY • Reported revenue of $203M down -10.41% YoY • Ionis anticipates full year 2026 revenue of $800M, a 20 percent year-over-year growth, with non-GAAP operating loss expected to be similar to 2025, excluding a one-time payment.
0 · Reply
Estimize
Estimize Feb. 25 at 11:00 AM
$IONS reported - EPS and - revenue for Q4. http://www.estimize.com/intro/ions?chart=historical&metric_name=eps&utm_content=IONS&utm_medium=
0 · Reply
Nosh
Nosh Feb. 24 at 1:55 PM
$IONS Could go much higher...volume is there but it may need a breather. Risk/reward is so so at best. On watch.
0 · Reply
RalphMBB
RalphMBB Feb. 19 at 12:14 AM
$IONS Wish I had bought more back in July. I checked and it was 23.5% of my portfolio. It has been my second best performer of '25. Great company and much valued innovatove medicines in development.
0 · Reply
Dr_Stoxx
Dr_Stoxx Feb. 18 at 4:25 PM
$IONS: long swing hold for me and I'll be dumping before the ER, but it does look primed here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 9:57 AM
$IONS RSI: 47.71, MACD: 0.6553 Vol: 2.17, MA20: 82.52, MA50: 80.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Fingerlickengood
Fingerlickengood Feb. 9 at 3:07 PM
$CDXS $IONS https://biz.chosun.com/en/en-science/2026/02/09/Z5RDWXQNSJDCREPPUK2VFBPFPU/
1 · Reply
johnnygogogo
johnnygogogo Feb. 5 at 11:23 PM
$IONS hey kiddos, Arrowhead is already taking market share. “And patients switching from Olezarsen” @skeezbag
1 · Reply